Myriad, Gene and UnitedHealthcare

Myriad Genetics plummets 20% as UnitedHealth changes GeneSight coverage
Myriad Genetics (NASDAQ:MYGN) is down ~20% in Friday trading following reports that UnitedHealth Group (UNH) will no longer cover the company's genetic test that helps to determine which mental health medications are likely to work with an individual patient.
Myriad Genetics in Active Talks with UnitedHealthcare to Keep Coverage of GeneSight
Myriad Genetics said it is in talks with UnitedHealthcare to ensure that enrollees continue to have access to its GeneSight mental health medication test after the insurer changed its coverage policy.
Myriad Genetics comments on UnitedHealthcare’s updated policy
Myriad Genetics (MYGN) was informed on Friday, November 1, 2024, of an updated medical policy from UnitedHealthcare restricting access to
Myriad weakness due to UnitedHealth coverage update, says Stephens
Stephens analyst Mason Carrico notes that Myriad Genetics (MYGN) shares are down about 20% this morning, which the firm blames on an announcement from UnitedHealth (UNH) stating that starting Jan. 1,
Myriad Genetics Shares Slip 21% on UnitedHealthcare Coverage Changes
Myriad Genetics stock was down 21%, to $17.30, in midday Friday trading. Shares of the diagnostic-test maker have fallen 34% over the past month. Starting Jan. 1, the UnitedHealth Group unit plans to discontinue coverage and remove prior authorization requirements for multi-panel pharmacogenetic codes, it said.
bovnews1d
The Myriad Genetics, Inc. Rollercoaster: What’s Behind the Latest MYGN Stock Fluctuation?
On Friday, Myriad Genetics, Inc. (MYGN) stock saw a decline, ending the day at $17.99 which represents a decrease of $-3.97 or -18.08% from the prior close of $21.96. The stock opened at $20.04 and ...
TD Cowen Reaffirms Their Hold Rating on Myriad Genetics (MYGN)
TD Cowen analyst Daniel Brennan maintained a Hold rating on Myriad Genetics (MYGN – Research Report) today and set a price target of ...
manilatimes21d
Myriad Genetics and jscreen™ Announce Strategic Partnership to Advance Health Equity and Genetic Testing Access
SALT LAKE CITY, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics Inc. (NASDAQ: MYGN), a leader in genetic testing and ...
Myriad Genetics Comments on UnitedHealthcare’s Updated Medical Policy for Pharmacogenetic Testing
Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, was informed on Friday, November 1 ...